CDRH’s Shuren: FDA’s 510(k) findings due soon

Dr. Jeffrey Shuren, head of the Food & Drug Administration’s medical device oversight arm, told a Massachusetts audience that results from the agency’s internal, soup-to-nuts review of its 510(k) clearance program are due out in a few weeks.

At the second in a series of "town hall" meetings in Woburn, Mass., the Center for Devices & Radiological Health’s leader said the federal watchdog would seek public comment on the report before making any changes to the program.

Shuren told MassDevice that the agency still hasn’t decided exactly what changes are in store for the 510(k) process.

"What we’ve been saying so far is not anything about what changes we’re going to make. There’s a lot of rumor mill about what we’re going to do, but we’ve not said we’re doing A, B, C or D specifically," he told us. "The only thing I’m very clear about is we’re not recommending to get rid of the 510(k) program."

Asked if the Obama administration is advocating for more stringent oversight of medical devices, Shuren said his department has been given free rein to police the industry as it sees fit.

"I have had absolutely no pressure or pushback from the administration. Even the commissioner of FDA, has, I think much to her credit, let the center do its own assessment, come back with its own recommendations," Shuren said. "I can tell you the things that we want to put out for the public have her full support in moving forward."

The FDA’s internal 520(k) review includes the feedback generated at the town hall meetings, Shuren said, as well as examinations of the agency’s database and a survey of its review staff and managers.

"I think one of the challenges for both industry and FDA on the 510(k) is that there have not been tools — very good metrics — put in place to access the effectiveness of the program. That’s something that needs to be addressed in the future. There’s been a lot of discussion, for example, of, "Well, we’re not seeing a lot of people dying across the country from medical devices on the market," he said. "Well, actually, people do get hurt by medical devices, but on the flip side no device is risk-free. The question is, were these anticipated risks and have we taken appropriate steps to mitigate to the extent we can? Nothing is going to be risk free.

Jeffrey Shuren

CDRH head Dr. Jeffrey Shuren

"The real test of the program is whether or not, when we’re making a decision for a device to go on the market, there are truly reasonable assurances of safety and effectiveness. That’s what the standard is — not whether a device made it on the market and it turned out to be unsafe," Shuren said. "The FDA is there to check to make sure it’s safe and effective before it goes on the market. It’s either safe and effective or it’s not before it’s coming to us. The same with medical devices. And that’s the real test of the 510(k) program and how it’s implemented. Is it good enough and are we implementing in a way that when a device gets on the market there truly are reasonable assurances of safety and effectiveness?"

To that end, he said, some companies applying for 510(k) clearance will be asked to submit more clinical data than in the past.

"Those decisions are case-by-case, based on the device. What we will try to address is, can we be more clear about when we would anticipate clinical data for a device?" Shuren told us.

Touching on the high-profile controversy over the FDA’s clearance of ReGen Biologics Inc.’s (OTC:RGBO) Menaflex knee cartilage implant, Shuren said that foofaraw wasn’t behind the scrutiny of the 510(k) protocol.

"A lot of people have asked did we do this over ReGen. The answer is no," he said "These issues we uncovered in 510(k) were circling around for a while."

Citing the programs origins in 1976, Shuren said the agency has tried over the years to adapt it as a path to market for lower-risk medical devices.

"FDA has tried to be flexible to squeeze through as many devices as possible, [but] as technology evolves it’s not as adequate," he said. "It’s not the first time we’ve done [a review] and it probably won’t be the last time. The world will change and we have to make appropriate mid-point adjustments."

In his opening remarks, Shuren said the message from the medical device industry has been consistent on one subject: The need for predictability along the regulatory pathway.

"I have heard a clear message from you: The FDA needs to provide industry with clear, predictable pathways to approval and clearance. We hear you. We agree. And we’re on it," Shuren said. "Providing clear, predictable pathways to market will also help foster innovation, which is the other theme we’ve been hearing. We agree with you on this front, as well."

To that end, he said, the agency is putting "concrete step we can take to be a smarter FDAs" into its strategic priorities for 2010.

"One such step is to make available our experts to help industry solve problems, not just identify them," Shuren explained. "For example, we’ve been collaborating with the University of Pennsylvania on open-source software for external infusion pumps that manufacturers can build on or use to benchmark their own products. In fact, we’ve offered to perform diagnostics on infusion pump software at any stage of development — even before the device lands at our doorstep."

More than 500 people attended Shuren’s first town hall meeting May 18 in Minneapolis, he said, noting that a scheduled town hall meeting in Los Angeles in October would be his last this year.

RSS From Medical Design & Outsourcing

  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]
  • Cosasco’s wireless communications protocol makes electrically hazardous areas safer
    Cosasco has expanded the functionality of its CWT-9020 wireless water system corrosion monitor for electrically hazardous areas by offering ISA100 Wireless communications protocol. Along with WirelessHART 7, the new protocol option allows the transmitter to integrate with an even wider range of existing wireless systems. ISA100 Wireless supports more wireless devices and provides an effective […]
  • Vicon captures a new development in motion capture (mocap)
    Vicon announced the launch of its new flagship camera platform, the Vicon Vantage. Drawing on over 30 years’ of motion capture (mocap) experience, the Vantage platform combines innovative technology with accessible design to open up motion capture to a broader audience. Vicon is a motion capture technology specialist company for science and life industries. Advances in […]
  • Satel’s latest product sets a new milestone in radio manufacturing
    The new Satelline TR4, from the Finnish manufacturer of radio data transmission systems, Satel sets a new milestone. The compact UHF transceiver with transmitting power of 1,000 mW is compatible with the protocols of Pacific Crest, Trimble and Satel. The type certifications in all important regions of the world make the TR4 ideal for integration […]
  • SCHURTER announces retirement of founder and management changes
    SCHURTER announced the retirement of founder Bruno H. Schurter on June 29, 2015. The company, founded in 1982 in Petaluma, California, will change management effective July 1, 2015. Bruno H. Schurter, president and CEO will retire after 33 years of heading up the privately held company, which is a subsidiary of SCHURTER Holding AG, founded in […]
  • Silicone: Expanding the horizon for modern medical devices
    Editor’s note: This article comes from Albright Technologies a manufacturer of custom silicone prototypes and provides volume production for medical, pharmaceutical, industrial, and other applications. Silicone materials have been around for more than 70 years. Beginning in the 1960s, silicones have played an important and evolving part in products designed for the medical field. Since that time, […]
  • DeNovo Sciences appoints a molecular diagnostics veteran as new CSO
    DeNovo Sciences, a producer of  liquid biopsy products, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo’s […]
  • Albright Technologies expands their silicone offerings
    Albright Technologies, a rapid silicone prototyper, has added silicone injection molding tooling and services to its product lineup. Liquid silicone injection molding became a suitable product offering as Albright expanded its offerings to better serve the silicone molding market. While silicone prototypes are commonly manufactured with low volumes in mind; injection molded liquid silicone rubber parts are […]
  • Applied Silver launches SilvaClean, silver treatment for textiles
    Applied Silver, Inc, is launching SilvaClean, a state-of-the-art silver treatment for textiles, at the Association for Professionals in Infection Control and Epidemiology’s (APIC) forty-second Annual Conference taking place at the Music City Center in Nashville, from June 27 through June 29. Hospitals have invested significantly in reducing the potential of infection through products and processes designed […]
  • Two-Component technology for improved quality of life
    In the field of injection molding and mold making, toolcraft covers all processes within the added value chain–from the design and selection of materials through to the creation of finished and qualified products. Complete solutions offered include injection molding for parts in the small and extremely small component areas, e.g. for medical technology. Utilizing two-component […]

Leave a Reply